Page 2597 - Hematology_ Basic Principles and Practice ( PDFDrive )

2312.e2 Part XIII Consultative Hematology

50. Chapman WC, Singla N, Genyk Y, et al: A phase 3, randomized, in Cardio Thoracic Surgery (REACTS). J Thorac Cardiovasc Surg
double-blind comparative study of the efficacy and safety of topical 133:1547–1552, 2007.
recombinant human thrombin and bovine thrombin in surgical hemo- 73. Pasquali SK, Hall M, Li JS, et al: Safety of aprotinin in congenital heart
stasis. J Am Coll Surg 205:256–265, 2007. operations: results from a large multicenter database. Ann Thorac Surg
51. Albala DM, Lawson JH: Recent clinical and investigational applica- 90:14–21, 2010.
tions of fibrin sealant in selected surgical specialties. J Am Coll Surg 74. Hedner U: Recombinant factor VIIa (Novoseven) as a hemostatic agent.
202:685–697, 2006. Semin Hematol 38:43–47, 2001.
52. Verstraete M: Clinical application of inhibitors of fibrinolysis. Drugs 75. Hedner U: Recombinant factor VIIa: its background, development and
29:236–261, 1985. clinical use. Curr Opin Hematol 14:225–229, 2007.
53. Henry DA, O’Connell DL: Effects of fibrinolytic inhibitors on mortal- 76. Boffard KD, Riou B, Warren B, et al: Recombinant factor VIIa as
ity from upper gastrointestinal haemorrhage. BMJ (Clinical Res Ed) adjunctive therapy for bleeding control in severely injured trauma
298:1142–1146, 1989. patients: two parallel randomized, placebo-controlled, double-blind
54. Fremes SE, Wong BI, Lee E, et al: Metaanalysis of prophylactic drug clinical trials. J Trauma 59:8–15, discussion -8, 2005.
treatment in the prevention of postoperative bleeding. Ann Thorac Surg 77. Knudson MM, Cohen MJ, Reidy R, et al: Trauma, transfusions, and
58:1580–1588, 1994. use of recombinant factor VIIa: A multicenter case registry report of
55. Laupacis A, Fergusson D: Drugs to minimize perioperative blood loss 380 patients from the Western Trauma Association. J Am Coll Surg
in cardiac surgery: meta-analyses using perioperative blood transfusion 212:87–95, 2011.
as the outcome. The International Study of Peri-operative Transfusion 78. Dutton RP, Parr M, Tortella BJ, et al: Recombinant activated factor VII
(ISPOT) Investigators. Anesth Analg 85:1258–1267, 1997. safety in trauma patients: results from the CONTROL trial. J Trauma
56. Munoz JJ, Birkmeyer NJ, Birkmeyer JD, et al: Is epsilon-aminocaproic 71:12–19, 2011.
acid as effective as aprotinin in reducing bleeding with cardiac surgery?: 79. Scarpelini S, Rizoli S: Recombinant factor VIIa and the surgical patient.
a meta-analysis. Circulation 99:81–89, 1999. Curr Opin Crit Care 12:351–356, 2006.
57. Henry DA, Moxey AJ, Carless PA, et al: Anti-fibrinolytic use for mini- 80. Friederich PW, Henny CP, Messelink EJ, et al: Effect of recombinant
mising perioperative allogeneic blood transfusion. Cochrane Database activated factor VII on perioperative blood loss in patients undergo-
Syst Rev (1):CD001886, 2001. ing retropubic prostatectomy: a double-blind placebo-controlled
58. Brown JR, Birkmeyer NJ, O’Connor GT: Meta-analysis comparing the randomised trial. Lancet 361:201–205, 2003.
effectiveness and adverse outcomes of antifibrinolytic agents in cardiac 81. Lodge JP, Jonas S, Oussoultzoglou E, et al: Recombinant coagulation
surgery. Circulation 115:2801–2813, 2007. factor VIIa in major liver resection: a randomized, placebo-controlled,
59. Zufferey P, Merquiol F, Laporte S, et al: Do antifibrinolytics reduce double-blind clinical trial. Anesthesiology 102:269–275, 2005.
allogeneic blood transfusion in orthopedic surgery? Anesthesiology 82. Amitrano L, Brancaccio V, Guardascione MA, et al: Inherited coagula-
105:1034–1046, 2006. tion disorders in cirrhotic patients with portal vein thrombosis. Hepatol-
60. Sukeik M, Alshryda S, Haddad FS, et al: Systematic review and meta- ogy 31:345–348, 2000.
analysis of the use of tranexamic acid in total hip replacement. J Bone 83. Diprose P, Herbertson MJ, O’Shaughnessy D, et al: Activated recom-
Joint Surg Br 93:39–46, 2011. binant factor VII after cardiopulmonary bypass reduces allogeneic
61. Crescenti A, Borghi G, Bignami E, et al: Intraoperative use of tranexamic transfusion in complex non-coronary cardiac surgery: randomized
acid to reduce transfusion rate in patients undergoing radical retropubic double-blind placebo-controlled pilot study. Br J Anaesth 95:596–602,
prostatectomy: double blind, randomised, placebo controlled trial. BMJ 2005.
(Clinical Res Ed) 343:d5701, 2011. 84. Mayer SA, Brun NC, Begtrup K, et al: Recombinant activated factor
62. Kauvar DS, Lefering R, Wade CE: Impact of hemorrhage on trauma VII for acute intracerebral hemorrhage. N Engl J Med 352:777–785,
outcome: an overview of epidemiology, clinical presentations, and 2005.
therapeutic considerations. J Trauma 60:S3–S11, 2006. 85. Mayer SA: Complications in patients with intracerebral hemorrhage
63. Shakur H, Roberts I, Bautista R, et al: Effects of tranexamic acid treated with recombinant factor VIIa. Neurology 69:319–320, 2007.
on death, vascular occlusive events, and blood transfusion in trauma 86. Roberts HR: Clinical experience with activated factor VII: focus on
patients with significant haemorrhage (CRASH-2): a randomised, safety aspects. Blood Coagul Fibrin 9(Suppl 1):S115–S118, 1998.
placebo-controlled trial. Lancet 376:23–32, 2010. 87. Roberts HR: Recombinant factor VIIa (Novoseven) and the safety of
64. Cap AP, Baer DG, Orman JA, et al: Tranexamic acid for trauma treatment. Semin Hematol 38:48–50, 2001.
patients: a critical review of the literature. J Trauma 71:S9–S14, 88. Thomas GO, Dutton RP, Hemlock B, et al: Thromboembolic
2011. complications associated with factor VIIa administration. J Trauma
65. Boylan JF, Klinck JR, Sandler AN, et al: Tranexamic acid reduces blood 62:564–569, 2007.
loss, transfusion requirements, and coagulation factor use in primary 89. Practice Guidelines for blood component therapy: A report by the
orthotopic liver transplantation. Anesthesiology 85:1043–1048, discus- American Society of Anesthesiologists Task Force on Blood Component
sion 30A-31A, 1996. Therapy. Anesthesiology 84:732–747, 1996.
66. Sharma V, Katznelson R, Jerath A, et al: The association between 90. Rebulla P: Platelet transfusion trigger in difficult patients. Transfus Clin
tranexamic acid and convulsive seizures after cardiac surgery: a multi- Biol 8:249–254, 2001.
variate analysis in 11 529 patients. Anaesthesia 69:124–130, 2014. 91. Clark P, Mintz PD: Transfusion triggers for blood components. Curr
67. Molenaar IQ, Warnaar N, Groen H, et al: Efficacy and safety of Opin Hematol 8:387–391, 2001.
antifibrinolytic drugs in liver transplantation: a systematic review and 92. Balduini CL, Noris P, Belletti S, et al: In vitro and in vivo effects of
meta-analysis. Am Soc Transplant 7:185–194, 2007. desmopressin on platelet function. Haematologica 84:891–896, 1999.
68. Hardy JF: Pharmacological strategies for blood conservation in cardiac 93. Noris M, Remuzzi G: Uremic bleeding: closing the circle after 30 years
surgery: erythropoietin and antifibrinolytics. Can J Anaesth 48:S24–S31, of controversies? Blood 94:2569–2574, 1999.
2001. 94. Dember LM: Critical care issues in the patient with chronic renal
69. Lecker I, Wang DS, Whissell PD, et al: Tranexamic acid-associated failure. Crit Care Clin 18:421–440, 2002.
seizures: Causes and treatment. Ann Neurol 79:18–26, 2016. 95. Moia M, Mannucci PM, Vizzotto L, et al: Improvement in the hae-
70. Murkin JM: Attenuation of neurologic injury during cardiac surgery. mostatic defect of uraemia after treatment with recombinant human
Ann Thorac Surg 72:S1838–S1844, 2001. erythropoietin. Lancet 2:1227–1229, 1987.
71. Mangano DT, Miao Y, Vuylsteke A, et al: Mortality associated with 96. Sohal AS, Gangji AS, Crowther MA, et al: Uremic bleeding: patho-
aprotinin during 5 years following coronary artery bypass graft surgery. physiology and clinical risk factors. Thromb Res 118:417–422, 2006.
JAMA 297:471–479, 2007. 97. Caldwell SH, Hoffman M, Lisman T, et al: Coagulation disorders and
72. Coleman CI, Rigali VT, Hammond J, et al: Evaluating the safety hemostasis in liver disease: pathophysiology and critical assessment of
implications of aprotinin use: the Retrospective Evaluation of Aprotinin current management. Hepatology 44:1039–1046, 2006.